Lindsey Draper, MD

Title(s)Adjunct Instructor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California San Francisco, San Francisco, California, San Francisco, CA06/2025Medical Oncology Fellowship
    Mount Sinai Hospital, New York, NY06/2022Internal Medicine Residency
    National Cancer Institute, Bethesda, MD06/2019Postdoctoral Cancer Research Training Award Fellow
    University of Maryland School of Medicine, Baltimore, MDMD05/2017Medicine
    National Cancer Institute, Bethesda, MD07/2013Post-baccalaureate Cancer Research Training Award Fellow
    Juniata College, Huntingdon, PABS05/2010Biology
    Collapse awards and honors
    Parker Institute for Cancer Immunotherapy2025  - 2027Early Career Research Award: Parker Scholar
    Gladstone-UCSF Institute of Genomic Immunology2025  - 2026Symbiont Seed Grant
    American Society of Clinical Oncology2024  - 20252024 Conquer Cancer Young Investigator Award
    Chan Zuckerberg Biohub - San Francisco 2023  - 2025Physician-Scientist Fellow

    Collapse Overview 
    Collapse overview
    Dr. Lindsey Draper is an Adjunct Instructor in the Department of Medicine at the University of California, San Francisco, where she specializes in the care of patients with ovarian cancer. As a physician-scientist in the Roybal Laboratory, she conducts research at the intersection of immunology and synthetic biology to develop novel immunotherapies for patients with ovarian cancer and other aggressive solid tumors. Her work focuses on genetically enhancing tumor-infiltrating lymphocytes (TILs) to overcome mechanisms of resistance in ovarian cancer, with the goal of creating safer and more effective treatment options.

    Dr. Draper brings extensive expertise in immunotherapy, including her prior work in the laboratory of Dr. Steven A. Rosenberg at the National Cancer Institute, where she contributed to efforts in TIL therapy and T-cell receptor discovery for HPV-associated cancers. This work led to multiple clinical trials that, for the first time, demonstrated that cellular therapeutics can induce responses in patients with epithelial malignancies.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. Sci Adv. 2025 Apr 11; 11(15):eadq4297. Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K. PMID: 40203088; PMCID: PMC11980841.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018 04 19; 3(8). Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. PMID: 29669936; PMCID: PMC5931134.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    3. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015 Oct 01; 21(19):4431-9. Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. PMID: 26429982; PMCID: PMC4603283.
      View in: PubMed   Mentions: 89     Fields:    
    4. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10; 33(14):1543-50. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. PMID: 25823737; PMCID: PMC4417725.
      View in: PubMed   Mentions: 307     Fields:    Translation:HumansCells
    Lindsey's Networks
    Concepts (47)
    Derived automatically from this person's publications.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _